Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. Company
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-09-29
71.69 CNY   -1.19%
09/27WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility
AQ
09/20Delivering On The Promise Of New Therapies For Rare Diseases : An Interview with Lili Mao, Director of Clinical Development Unit and Head of Project Management Office at GEXVal
PU
09/20Delivering On The Promise Of New Therapies For Rare Diseases : An Interview with Xinyu Zhao, Professor, Waisman Center and Department of Neuroscience, University of Wisconsin-Madison
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:

- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;

- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;

- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;

- other (0.1%).

Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Sales per Business
2021
Chemical14 087.2061.5%
Testing4 525.1119.8%
Biology1 985.098.7%
Domestic New Drug Research and Development1 251.045.5%
Cell and Gene Therapy CTDMO1 026.404.5%
Inter-Segment Offset27.520.1%
CNY in Million
Sales per region
20202021Delta
United States8 861.9153.6%12 146.4053% +37.06%
China4 145.3325.1%5 802.2425.3% +39.97%
Europe2 650.7816%3 719.3016.2% +40.31%
Rest of Asia679.654.1%1 026.314.5% +51.01%
Other Regions197.761.2%208.110.9% +5.24%
CNY in Million
Managers
Name Title Age Since
Min Zhang Chen Co-Chief Executive Officer & Executive Director 51 2022
Qing Yang Co-CEO, Executive Director & Executive VP 52 2020
Ge Li, Dr. Chairman & President 55 -
Ellis Chu Co-Chief Financial Officer & Senior Vice President - -
Ming Shi Co-Chief Financial Officer 46 2022
Florence Shi Chief Financial Officer 47 2022
Frederick Hausheer Chief Medical Officer - 2019
Guo Dong Tong Chief Operating Officer & Senior Vice President - -
Edward Hu Vice Chairman & Chief Investment Officer 59 2020
Chi Yao Co-Secretary - 2016
Members of the board
Name Title Age Since
Ge Li, Dr. Chairman & President 55 -
Harry He Chairman-Supervisory Board 55 2016
Jiang Nan Cai, Dr. Independent Non-Executive Director 64 2017
Yan Liu Independent Non-Executive Director 48 -
He Tong Lou, Dr. Independent Non-Executive Director 59 2017
Xiao Tong Zhang Independent Director 53 2017
Edward Hu Vice Chairman & Chief Investment Officer 59 2020
Ning Zhao, Dr. Executive Director & Senior Vice President 55 -
Zhao Hui Zhang Director & Senior Vice President-Operations 52 2000
Min Zhang Chen Co-Chief Executive Officer & Executive Director 51 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,571,227,566 1,928,313,371 75.0% 6,158,178 0.2% 64.9%
Stock B 0 401,399,332 0 0.0% 6,134,126 1.5%
Shareholders
NameEquities%
Ge Li 716,861,440 28.0%
Pavilion Capital Pte Ltd 159,160,073 6.22%
Shanghai Zhongmin Yinfu Capital Management Co. Ltd. 116,098,013 4.54%
Zhong Ou Asset Management Co., Ltd 89,122,218 3.48%
China Universal Asset Management Co., Ltd. 74,679,967 2.92%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 64,416,499 2.52%
Yinhua Fund Management Co., Ltd. 54,777,161 2.14%
ICBC Credit Suisse Asset Management Co., Ltd. 54,582,073 2.13%
E Fund Management Co., Ltd. 41,305,316 1.61%
Hai Shan Zhou 38,724,998 1.51%
Holdings
NameEquities%Valuation
CLARITY MEDICAL GROUP HOLDING LIMITED (1406) 78,125,196 15.0% 14,930,506 USD
JW (CAYMAN) THERAPEUTICS CO. LTD (2126) 15,232,570 3.71% 11,896,789 USD
CANBRIDGE PHARMACEUTICALS INC. (1228) 40,346,960 9.51% 10,743,589 USD
SENSORION (ALSEN) 5,249,608 6.57% 2,591,889 USD
Markets and indexes
- A-share
- SSE 50 /
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  603259.SH
- Datastream Code :  
Company contact information
WuXi AppTec Co., Ltd.
5 Bridge
CN-JS 214092 Wuxi

Phone : +86 (21) 5046-1111
Fax : +86 (21) 5046-1000
web site : https://www.wuxiapptec.com/
Brand Portfolio
In partnership withAllbrands.markets
More brands of WuXi AppTec Co., Ltd.